SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-40960-0
- By:
- Publication type:
- Article
Works by Zarbiv, Gila
Results: 5
1
2
Kinetics of Maternally Derived Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies in Infants in Relation to the Timing of Antenatal Vaccination.
- Published in:
- Clinical Infectious Diseases, 2023, v. 76, n. 3, p. e274, doi. 10.1093/cid/ciac480
- By:
- Publication type:
- Article
3
Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Neutralization After Antenatal Messenger RNA Vaccination.
- Published in:
- Clinical Infectious Diseases, 2022, v. 75, n. 11, p. 2023, doi. 10.1093/cid/ciac395
- By:
- Publication type:
- Article
4
Effect of Gestational Age at BNT162b2 mRNA Vaccination on Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Levels.
- Published in:
- Clinical Infectious Diseases, 2022, v. 75, n. 1, p. e603, doi. 10.1093/cid/ciac135
- By:
- Publication type:
- Article
5
Efficient Maternofetal Transplacental Transfer of Anti- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Antibodies After Antenatal SARS-CoV-2 BNT162b2 Messenger RNA Vaccination.
- Published in:
- Clinical Infectious Diseases, 2021, v. 73, n. 10, p. 1909, doi. 10.1093/cid/ciab266
- By:
- Publication type:
- Article